ACM
PBE icon

Arlington Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Arlington Capital Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-271,368
Closed -$12.8M – 58
2018
Q4 		$12.8M Sell
271,368
-278,343
-51% -$14.3M 9.48% 4
2018
Q3 		$32.7M Buy
+549,711
New +$32.1M 16.08% 4

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arlington Capital Management's PBE Position: Q1 2019 in Review

Arlington Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2019, closing a stake of 271,368 shares — an estimated $12.8M sold.

Arlington Capital Management first reported a position in PBE in Q3 2018 and held it in 2 quarters. The position peaked at $32.7M in Q3 2018. 81 funds tracked by Wall St. Rank hold PBE as of Q1 2019.

  • Arlington Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2019 after selling out during the quarter.
  • Arlington Capital Management sold 271,368 Invesco Biotechnology & Genome ETF shares in Q1 2019, an estimated $12.8M.
  • Arlington Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2018 and held it in 2 quarters.
  • Arlington Capital Management's Invesco Biotechnology & Genome ETF position peaked at $32.7M in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2019.

Based on Arlington Capital Management's 13F filing for Q1 2019, filed 10 May 2019.